Algert Global LLC Cytom X Therapeutics, Inc. Transaction History

Algert Global LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.53 - $2.89 $46,420 - $87,682	30,340 New	30,340 $56,000
Q1 2020 May 13, 2020	SELL	$3.61 - $8.6 $116,974 - $278,665	-32,403 Closed	0 $0
Q4 2019 Feb 18, 2020	BUY	$5.17 - $8.91 $59,765 - $102,999	11,560 Added 55.46%	32,403 $269,000
Q3 2019 Nov 14, 2019	SELL	$7.38 - $12.25 $208,706 - $346,430	-28,280 Reduced 57.57%	20,843 $154,000
Q2 2019 Aug 14, 2019	BUY	$9.35 - $11.41 $459,300 - $560,493	49,123 New	49,123 $551,000
Q1 2019 May 01, 2019	SELL	$9.5 - $19.16 $718,067 - $1.45 Million	-75,586 Closed	0 $0
Q4 2018 Feb 01, 2019	BUY	$12.69 - $18.61 $111,380 - $163,339	8,777 Added 13.14%	75,586 $1.14 Million
Q3 2018 Nov 14, 2018	BUY	$18.04 - $26.41 $814,668 - $1.19 Million	45,159 Added 208.59%	66,809 $1.24 Million
Q2 2018 Aug 02, 2018	BUY	$21.38 - $29.68 $7,483 - $10,388	350 Added 1.64%	21,650 $495,000
Q1 2018 May 03, 2018	SELL	$21.76 - $34.22 $651,342 - $1.02 Million	-29,933 Reduced 58.43%	21,300 $606,000
Q4 2017 Feb 01, 2018	BUY	$19.0 - $23.09 $102,220 - $124,224	5,380 Added 11.73%	51,233 $1.08 Million
Q3 2017 Nov 17, 2017	BUY	$13.53 - $18.17 $620,391 - $833,149	45,853	45,853 $833,000

49.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $55.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.